Vanguard Group
INBX

Vanguard Group’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Vanguard Group’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,861,469
Closed -$65.1M – 4524
2024
Q1 		$65.1M Sell
1,861,469
-12,854
-0.7% -$469K ﹤0.01% 2058
2023
Q4 		$71.2M Buy
1,874,323
+84,512
+5% +$1.81M ﹤0.01% 2028
2023
Q3 		$32.8M Buy
1,789,811
+18,271
+1% +$382K ﹤0.01% 2334
2023
Q2 		$46M Sell
1,771,540
-3,741
-0.2% -$87.4K ﹤0.01% 2220
2023
Q1 		$33.5M Buy
1,775,281
+14,908
+0.8% +$347K ﹤0.01% 2361
2022
Q4 		$43.4M Buy
1,760,373
+292,455
+20% +$8.6M ﹤0.01% 2250
2022
Q3 		$26.3M Buy
1,467,918
+111,802
+8% +$2.02M ﹤0.01% 2511
2022
Q2 		$15.4M Buy
1,356,116
+138,003
+11% +$2.03M ﹤0.01% 2774
2022
Q1 		$27.1M Buy
1,218,113
+11,365
+0.9% +$290K ﹤0.01% 2610
2021
Q4 		$52.7M Buy
1,206,748
+527,223
+78% +$21.1M ﹤0.01% 2316
2021
Q3 		$22.6M Buy
679,525
+184,676
+37% +$5.62M ﹤0.01% 2799
2021
Q2 		$13.6M Buy
494,849
+107,957
+28% +$2.25M ﹤0.01% 3050
2021
Q1 		$7.76M Buy
386,892
+6,043
+2% +$176K ﹤0.01% 3297
2020
Q4 		$12.6M Buy
380,849
+350,849
+1,169% +$9.34M ﹤0.01% 2874
2020
Q3 		$540K Buy
+30,000
New +$544K ﹤0.01% 3800

Other funds holding INBX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Vanguard Group's INBX Position: Q2 2024 in Review

Vanguard Group sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2024, closing a stake of 1,861,469 shares — an estimated $65.1M sold.

Vanguard Group first reported a position in INBX in Q3 2020 and held it in 15 quarters. The position peaked at $71.2M in Q4 2023. 2 funds tracked by Wall St. Rank hold INBX as of Q2 2024.

  • Vanguard Group reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Vanguard Group sold 1,861,469 Inhibrx, Inc. Common Stock shares in Q2 2024, an estimated $65.1M.
  • Vanguard Group first reported a position in Inhibrx, Inc. Common Stock in Q3 2020 and held it in 15 quarters.
  • Vanguard Group's Inhibrx, Inc. Common Stock position peaked at $71.2M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2024.

Based on Vanguard Group's 13F filing for Q2 2024, filed 13 Aug 2024.